GlycoMimetics' Focus Is On AML Therapy [Seeking Alpha]
GlycoMimetics, Inc. (GLYC)
Last glycomimetics, inc. earnings: 5/1 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.glycomimetics.com/investor-relations
Company Research
Source: Seeking Alpha
SummaryGlycoMimetics is conducting a Phase 3 trial of Uproleselan for acute myeloid leukemia.Cash on hand is sufficient to get to the top-line data release.The company stock is attractively valued.GlycoMimetics (GLYCglycoproteinsUproleselan for AMLUproleselan is anE-selectinuproleselan Phase 2 trialThe AML therapy landscape has been changing rapidly. A few years ago, there was nothing new beyond standard chemotherapy. Now, several new drugs are commercially available or in clinical pipelines. However, they tend totarget specific mutationsAGIOHow much is that worth, presuming Phase 3 results are positive and the FDA approves the drug? It depends on pricing and physician decisions, so revenue estimates can vary widely. There are about new 10,500 cases of AML in the U.S. each year. If uproleselan with standard chemotherapy becomes the standard of care, a reasonable estimate of annual revenue, at a price of $50,000, is about $0.5 billion. Less, if priced below that. If other therapies pro
Show less
Read more
Impact Snapshot
Event Time:
GLYC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLYC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLYC alerts
High impacting GlycoMimetics, Inc. news events
Weekly update
A roundup of the hottest topics